Daniel Kaemmerer

Dr. Daniel Kaemmerer


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
DKDaniel Kaemmerer
Daniel Kaemmerer
LPLuisa Peter
Luisa Peter
ALAmelie Lupp
Amelie Lupp
SSStefan Schulz
Stefan Schulz
JSJörg Sänger
Jörg Sänger
RBRichard Paul Baum
Richard Paul Baum

14 July 2015 in Oncotarget
Verified
Journal Article
Open access
DKDaniel Kaemmerer
Daniel Kaemmerer
TTTina Träger
Tina Träger
MHMaike Hoffmeister
Maike Hoffmeister
BSBence Sipos
Bence Sipos
MHMerten Hommann
Merten Hommann
ALAmelie Lupp
Amelie Lupp
Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy

30 December 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
DKDaniel Kaemmerer
Daniel Kaemmerer
CRChristiane Reimann
Christiane Reimann
ESElisa Specht
Elisa Specht
RWRalph M. Wirtz
Ralph M. Wirtz
MSManal Sayeg
Manal Sayeg
ALAmelie Lupp
Amelie Lupp
Introduction: For many tumors, the overexpression of the chemokine receptor CXCR4 is associated with increased malignancy and poor patient outcomes. However, comprehensive data for neuroendocrine neoplasms of the lung are still lacking.

1 February 2012 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
DKDaniel Kaemmerer
Daniel Kaemmerer
VPVikas Prasad
Vikas Prasad
WDWolfgang Daffner
Wolfgang Daffner
SHSven-Petter Haugvik
Sven-Petter Haugvik
SSStefan Senftleben
Stefan Senftleben
MHMerten Hommann
Merten Hommann
Previous studies of the intraoperative use of a hand-held gamma probe to localize metastases and primary tumors have shown improved assessment of tumor spread and changes in surgical management based on additional information gained by radioguided surgery (RGS). The aim was to test the feasibility and advantages of doing RGS using a gallium-68 labeled with somatostatin receptor analogs in the intraoperative detection of neuroendocrine tumors. Ga-68 somatostatin receptor PET/CT imaging was performed preoperatively in 9 patients with gastroenteropancreatic neuroendocrine tumors. Statistical analyses were performed to find out the correlation between the pathologic size of the tumor lesions and the maximum standardized uptake value on PET/CT as well as the target/nontarget ratio (T/NT) of gamma probe counts. Thereafter, the impact of the planned operation procedure and the lesion-based sensitivity of tumor detection (surgical palpation vs. PET/CT vs. gamma probe) had been observed. Overall, 72 locations in 9 patients were examined intraoperatively using gamma probes. The gamma probe detected 94% of the whole histologically quantified lesions, whereas the PET/CT allocated 69% and surgical palpation, 50%. RGS resulted in change in the operative procedure in 56%. There was a significant correlation between the maximum standardized uptake value and tumor size (0.74; P < 0.005). Hand-held gamma probe surgery using gallium-68-labeled somatostatin analogs is a feasible and an attractive option for real-time detection of small metastases and primaries of neuroendocrine tumors.

28 December 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DKDaniel Kaemmerer
Daniel Kaemmerer
RSRobin Schindler
Robin Schindler
FMFranziska Mußbach
Franziska Mußbach
Uta DahmenUta Dahmen
Uta Dahmen
AAAnnelore Altendorf-Hofmann
Annelore Altendorf-Hofmann
ALAmelie Lupp
Amelie Lupp
Hepatocellular (HCC) and cholangiocellular carcinomas (CCC) display an exceptionally poor prognosis. Especially for advanced disease no efficient standard therapy is currently available. Recently, somatostatin analogs have been evaluated for the treatment of HCC, however, with contradictory results. Besides, for both malignancies the chemokine receptor CXCR4 has been discussed as a possible new target structure. Expression of somatostatin receptor (SSTR) subtypes 1, 2A, 3, 4, and 5, and of CXCR4 was evaluated in a total of 71 HCCs and 27 CCCs by immunohistochemistry using well-characterized novel monoclonal antibodies. In HCC tumor cells, frequency and intensity of expression of SSTRs and CXCR4 were only low. CXCR4 was present in about 40% of the HCCs, although at a low intensity. SSTR5, SSTR2, and SSTR3 were detected in about 15%, 8%, and 5% of the HCC tumors, respectively. SSTR and CXCR4 expression was much higher in CCC than in HCC. CXCR4 and SSTR1 were present in 60% and 67% of the CCC samples, respectively, followed by SSTR2 and SSTR5, which were detected in 30% and 11% of the tumors, respectively. Most notably, CXCR4 was intensely expressed on the tumor capillaries in about 50% of the HCCs and CCCs. CXCR4 expression on tumor vessels was associated with poor patient outcomes. CCC, but not HCC, may be suitable for SSTR-based treatments. Because of the predominant expression of SSTR1, pan-somatostatin analogs should be preferred. In both HCC and CCC, indirect targeting of tumors via the CXCR4-positive tumor capillaries may represent a promising additional therapeutic strategy.

19 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ABAntonia Busse
Antonia Busse
LMLiliana H. Mochmann
Liliana H. Mochmann
CSChristiane Spenke
Christiane Spenke
RARuza Arsenic
Ruza Arsenic
FBFranziska Briest
Franziska Briest
PGPatricia Grabowski
Patricia Grabowski
Checkpoint inhibitors have shown promising results in a variety of tumors; however, in neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), low response rates were reported. We aimed herein to investigate the tumor immune microenvironment in NET/NEC to determine whether checkpoint pathways like programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) might play a role in immune escape and whether other escape mechanisms might need to be targeted to enable a functional antitumor response. Forty-eight NET and thirty NEC samples were analyzed by immunohistochemistry (IHC) and mRNA immunoprofiling including digital spatial profiling. Through IHC, both NET/NEC showed stromal, but less intratumoral CD3+ T cell infiltration, although this was significantly higher in NEC compared to NET. Expression of PD1, PD-L1, and T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) on immune cells was low or nearly absent. mRNA immunoprofiling revealed low expression of IFNγ inducible genes in NET and NEC without any spatial heterogeneity. However, we observed an increased mRNA expression of chemokines, which attract myeloid cells in NET and NEC, and a high abundance of genes related to immunosuppressive myeloid cells and genes with immunosuppressive functions like CD47 and CD74. In conclusion, NET and NEC lack signs of an activation of the adaptive immune system, but rather show abundance of several immunosuppressive genes that represent potential targets for immunomodulation.